The ABCC1 Knockout Huh-7 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal cell population in which the ABCC1 (MRP1) gene has been disrupted in the Huh-7 human hepatocellular carcinoma cell line. This polyclonal knockout pool is generated through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous mixture of edited alleles without isolation of individual clones. The population provides a loss-of-function model for studying the role of the ABCC1 efflux transporter in drug transport and resistance pathways within a liver cancer background.
Huh-7 is a widely used epithelial hepatocellular carcinoma cell line originally derived from a human liver tumor. It retains many hepatocyte-like features and is employed extensively in studies of liver cancer biology, drug metabolism, hepatotoxicity, and pharmacokinetics. The Huh-7 line serves as a relevant cellular context for evaluating the impact of transporter gene knockouts on chemotherapeutic sensitivity and hepatic clearance mechanisms.
ABCC1 encodes multidrug resistance-associated protein 1 (MRP1), an ATP-binding cassette transporter that functions as an ATP-dependent efflux pump for glutathione conjugates, leukotriene C4, and chemotherapeutic agents. ABCC1 expression is transcriptionally regulated by the Nrf2?CARE axis, where NFE2L2 (Nrf2) binds the antioxidant response element (ARE) after KEAP1 dissociation. Additional regulators include NFKB1, NR1I2 (PXR), and STAT3, which modulate ABCC1 under stress and inflammatory conditions. ABCC1 interacts with scaffold proteins ezrin (EZR), PDZK1, and radixin (RDX) at the plasma membrane, facilitating its localization and coupling to drug efflux.
In the context of hepatocellular carcinoma, ABCC1-mediated drug efflux is a major contributor to multidrug resistance, limiting the efficacy of anthracyclines, vinca alkaloids, and other chemotherapeutics. Disruption of ABCC1 in Huh-7 polyclonal knockout cells is expected to impair the extrusion capacity, leading to intracellular accumulation of cytotoxic substrates and potentially enhancing chemosensitivity. This model allows researchers to dissect the specific contribution of MRP1 to drug resistance and to explore mechanisms of resistance reversal in a liver cancer setting. Additionally, the knockout may be used to study the hepatobiliary elimination of glutathione conjugates and the role of ABCC1 in protecting cells from oxidative stress and drug-induced injury.
Applications include drug resistance reversal studies, hepatocellular carcinoma chemosensitivity screening, and pharmacological profiling of ABC transporter substrates. Functional assays such as calcein-AM efflux, ATPase activity, and leukotriene C4 transport quantify ABCC1 activity. Molecular analysis via Western blotting and RT-qPCR confirms knockout. Cell viability assays (MTT) with chemotherapeutics measure chemosensitivity changes, enabling investigation of Nrf2-dependent resistance and transporter-targeted interventions. For further details, contact Ascent Research.
